Drugs / JNJ-87704916
last change Apr 2024 re-read 2 minutes ago

JNJ-87704916

Developed for
neoplasm
Investigated by
Johnson & Johnson Enterprise Innovation Inc.

Trials 1 · a red edge is where a trial was stopped

2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06311578 Apr 2024 → Nov 2028 expected neoplasm Johnson & Johnson Enterprise Innovation Inc. Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as JNJ-87704916 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06311578